![Huma Qamar](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 6 122 $ op 31-05-2026
Huma Qamar formerly worked at Ocugen, Inc., as Chief Medical Officer from 2024 to 2026, Quantum BioPharma Ltd., as Head-Research & Development, and Medicus Pharma Ltd., as Chief Scientific Officer from 2023 to 2024.
Dr. Qamar received her doctorate degree from Army Medical College.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-04-2026 | 4.436 ( 0% ) | 6 122 $ | 31-05-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| OCUGEN, INC. | Hoofd Techniek/Wetenschap/O&O | 08-05-2026 |
| QUANTUM BIOPHARMA LTD. | Hoofd Techniek/Wetenschap/O&O | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 3 |
|---|---|
Army Medical College
 Army Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FSD Pharma, Inc.
 FSD Pharma, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurodegenerative, inflammatory and metabolic disorders | Health Technology |
Ocugen, Inc.
 Ocugen, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapy products | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
